Document is current

Article History

Received: 28 January 2025

Accepted: 29 June 2025

First Online: 18 July 2025

Declarations

:

: Hiroko Bando received honorarium from Pfizer, Eli Lilly, Chugai Pharmaceutical Co., and Kyowa Kirin. Aya Ueda has nothing to disclose. Kaori Terata received honorarium from Eli Lilly, Daiichi-Sankyo, Pfizer, AstraZeneca, Chugai, Taiho, and Kyowa Kirin. Mihoko Doi has nothing to disclose. Shigenori Nagai received honorarium from Chugai Pharmaceutical Co., Eisai, Pfizer, Daiichi-Sankyo, AstraZeneca, Eli Lilly, and MSD. Masaya Hattori received honorarium from Eli Lilly and Pfizer. Kenichi Watanabe received honorarium from AstraZeneca, Daiichi-Sankyo, Eisai, Shionogi, Kyowa Kirin, Nippon-Kayaku, Novartis, Eli Lilly, Taiho, Chugai Pharmaceutical Co., and Pfizer. Nobuko Tamura received a grant from Eisai; and received honorarium from Chugai Pharmaceutical Co., Pfizer, Eli Lilly, Novartis, Eisai, and AstraZeneca. Manabu Futamura received honorarium from Chugai Pharmaceutical Co., Taiho, Kaken-Seiyaku, Nippon-Kayaku, Daiichi-Sankyo, AstraZeneca, Pfizer, Eli Lilly, and Eisai. Kei Koizumi received honorarium from Chugai Pharmaceutical Co. and Pfizer. Naoki Niikura received grants or contracts from Chugai Pharmaceutical Co., Pfizer, Eisai, Mochida, Daiichi-Sankyo, and Novartis; and received honorarium from Chugai Pharmaceutical Co., Pfizer, Eli Lilly, MSD, Daiichi-Sankyo, and AstraZeneca. Tempei Miyaji received consulting fees from Pfizer. Yasuaki Muramatsu is an employee and stockholder of Pfizer Inc. Linghua Xu is an employee and stockholder of Pfizer Inc. Norikazu Masuda received honorarium from Chugai Pharmaceutical Co., Pfizer, AstraZeneca, Eli Lilly, and Daiichi-Sankyo; and received institutional support from Chugai Pharmaceutical Co., Eli Lilly, AstraZeneca, Pfizer, Daiichi-Sankyo, MSD, Eisai, Novartis, Gilead Sciences, and Ono Pharmaceutical; board of directors (unpaid) of Japan Breast Cancer Research Group Association (JBCRG). Shigehira Saji received honorarium from Chugai Pharmaceutical Co., Eisai, Taiho Pharmaceutical, Pfizer, Novartis, Kyowa Kirin, Daiichi-Sankyo, AstraZeneca, Eli Lilly, MSD, Ono Pharmaceutical, Takeda, and Exact Sciences; and had a consulting or advisory role in Kyowa Kirin, Chugai Pharmaceutical Co., Roche/Genentech, Daiichi-Sankyo/UCB Japan, and MSD; received research funding from Chugai Pharmaceutical Co., Taiho, Daiichi-Sankyo/UCB Japan, MSD, AstraZeneca, and Sanofi.

: The study was conducted in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the Ministry of Health, Labour and Welfare and the Declaration of Helsinki.

: Informed consent was obtained from all individual participants included in the study.